NGF and cancer: Additionally, there are two ongoing clinical trials, one testing the analgesic efficacy of a TrkA inhibitor on cancer patients with solid tumors or lymphoma (phase I, NCT03556228) and the other measuring the efficacy of anti-NGF monoclonal antibody tanezumab in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy (phase III, NCT02609828).